The apheresis market was valued at approximately USD 1,639 million in 2020, and it is expected to witness a revenue of USD 2580 million in 2026, with a CAGR of 7.85% over the forecast period, 2021-2026.
The apheresis market is expected to be positively impacted during the COVID-19 pandemic owing to the extensive application of plasma therapy in the treatment of COVID-19 infected patients. Furthermore, in August 2020, the US FDA granted emergency use authorization (EUA) of convalescent plasma (CCP) therapy in hospitalized individuals with COVID-19. Also, in April 2020, Terumo BCT Inc. and Marker Therapeutics AG received the FDA approval for the Emergency Use Authorization (EUA) of Terumo BCT’s Spectra Optia Apheresis System combined with Marker Therapeutics’ D2000 Adsorption Cartridge to treat patients aged 18 years or above with confirmed COVID-19 disease. Thus, given the wide usage of apheresis units in the treatment of COVID-19 patients and increasing product approvals by the FDA, the apheresis market enjoys a positive growth over the pandemic.
The propelling factors for the growth of the apheresis market include the increasing number of diseases, a rise in the demand for blood components and associated safety, technological advancement in the development of new apheresis techniques, and a rise in the reimbursement policies and funding for apheresis procedures.
The use of apheresis in clinically ill patients is increasing day by day, and it has been widely used as the primary therapy or as an adjunct to other treatments for various diseases, such as thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, drug toxicities, autoimmune disease, sepsis, and fulminant hepatic failure.
Additionally, as per the Centers for Disease Control and Prevention (CDC) 2019 report, it is estimated that about 37 million (15%) adults in the United States had chronic kidney disease (CKD). Apheresis plays a vital role in the purification of blood in patients with kidney disorders and drives the studied market. Along with these factors, the increasing product innovations and approvals have been driving the market growth. For instance, in June 2020, Fresenius Kabi AG and Fresenius Kabi USA received FDA clearance for ALYX Component Collection System, which is intended for use in blood collection establishments to collect and separate whole blood into its components. Thus, owing to the aforementioned factors, the apheresis market is expected to witness healthy growth over the forecast period.
Key Market Trends
The Hematological Disorders Segment is Expected to Grow the Fastest during the Forecast Period
Hematological disorders make a substantial contribution to the morbidity and mortality of individuals across the globe. According to the World Federation of Hemophilia report 2019, the number of people identified with hemophilia increased from 78,629 in 1999 to 324,648 in 2019 globally. Furthermore, about 157,517 people across the world are suffering from hemophilia A, and about 31,997 people are suffering from hemophilia B. Hence, owing to the increasing burden of hematological incidences and growing applications of apheresis as a treatment method for hematological disorders, the apheresis market for hematological disorders is expected to experience growth in the forecast period. The recent years brought about a rise in new options of therapeutic aphereses, such as immunoadsorption, double filtration, and cytapheresis used in the treatment of both primary and secondary autoimmune renal diseases. Additionally, as per ClinicalTrails.gov, as of January 21, 2021, there are about 47 ongoing clinical trials related to apheresis for different hematological disease development across the United States.
According to the research article published in the Journal of Thrombosis and Thrombolysis, 2020, coagulation parameters such as D-dimer, platelet count, fibrinogen, prothrombin time (PT), or activated partial thromboplastin time (aPTT) were found to be often increased in severe COVID-19 cases with an increased risk of thromboembolic complications, and thus, can indirectly impact the studied segment during the pandemic.
Furthermore, apheresis plays a very crucial role in the management of sickle cell anemia disease. As per the study titled, “Role of Emergency Automated Red Cell Exchange in Sickle Cell Crisis: A Case Report”, published in November 2020, apheresis equipment was found to provide better management in red cell exchange therapeutic procedures being performed in sickle cell. Thus, owing to the aforementioned factors, the application of apheresis in treating various hematological disorders is expected to grow significantly over the forecast period.
North America Holds the Major Share in the Studied Market and is Expected to Exhibit the Same Trend over the Forecast Period
The growing burden of various ailments related to blood such as kidney diseases, metabolic diseases, cancer, and neurological disorders, the presence of established healthcare infrastructure, and high patient awareness levels are the major factors driving the growth of the studied market in North America. According to the Leukemia & Lymphoma Society (LLS), approximately every three minutes, one person in the United States is being diagnosed with blood cancer. An estimated combined total of 178,520 people in the United States were expected to be diagnosed with leukemia, lymphoma, or myeloma in 2020. The new cases of leukemia, lymphoma, and myeloma accounted for 9.9% of the estimated 1,806,590 new cancer cases diagnosed in the United States in 2020. The high incidence of target diseases thus drives the studied market growth.
In May 2020, the Department of Defense in the United States began an effort to collect 8,000 donated units of plasma from patients who have recovered from COVID-19 to support the development of an effective treatment against the disease. This effort has given rise to the adoption of plasmapheresis devices and disposables in the United States.
Additionally, the increasing product approvals and presence of most of the major players in the region play a vital role in the growth of the studied market. For instance, in October 2020, Haemonetics Corporation received the FDA approval for its NexSys PCS system with Persona technology for plasma collection based on an individual donor’s body composition. Thus, the aforementioned factors are associated with the significant growth of the apheresis market in North America over the forecast period.
The market studied is moderately competitive and is dominated by a few major players, and currently, the market is well established in many areas and has shown nascent success history. However, its full potential is yet to be determined in the developing regions. With increasing government initiatives, there is an awareness among people, which is further driving the growth of the market studied. Additionally, the strategic alliances and new product launches by the major companies are expected to drive the market growth. For instance, in January 2020, Fresenius Kabi invested EUR 30 million for the expansion of a transfusion and apheresis disposables plant in the Dominican Republic.
The market estimate (ME) sheet in Excel format 3 months of analyst support
Our reports have been used by over 10K customers, including:
The anesthesia monitoring devices market was valued at approximately USD 1,764.41 million in 2020, and it is expected to reach USD 3,284.52 million by 2026, registering a CAGR of 10.60% during the forecast period, 2021-2026. In the early phase of the pandemic, due to the increasing cases of COVID-19, all hospitals, globally, had canceled...
The home sequential compression devices market in Europe is expected to grow from US$ 262.91 million in 2021 to US$ 405.94 million by 2028; it is estimated to grow at a CAGR of 6.4% from 2021 to 2028. Venous insufficiency disorders can be treated by procedures such as compression stockings and wraps, venopneumatic compression pumps,...
The global nuclear medicine market is projected to reach USD 7.5 billion by 2026 from USD 4.8billion in 2021, at a CAGR of 9.0% during the forecast period. Growth in the nuclear medicine market can primarily be attributed to factors such as the increasing incidence and prevalence of cancer and cardiac ailments and initiatives to lessen the...
The personal mobility devices market is expected to register a CAGR of nearly 5.85%, with a revenue of approximately USD 8,163.99 million in 2020, and it is expected to reach USD 11,527.84 million by 2026. Many people with chronic conditions or people with physical disabilities are not able to follow the guidelines and procedures to...
The patient monitoring systems market registered a market size of USD 26,198 million in 2020, and it is expected to reach 34,310 million by 2026, registering a CAGR of 8.87% during the forecast period. The growth of the patient monitoring market is attributed to the rising burden of chronic diseases due to lifestyle changes, growth in the...
The global interventional radiology market is projected to register a CAGR of 6.47% during the forecast period, with a revenue of USD 21,261.62 million in 2020 and expected to reach USD 31,262.67 million by 2026 The COVID-19 outbreak showed the impact on the interventional radiology market, as hospital and healthcare services were...
Interventional Cardiology Devices Market was valued at USD 13.11 billion in 2020, and is projected to reach a value of USD 20.07 billion by 2026, is expected to grow annually by 7.48% CAGR 2021-2026. The Interventional Cardiology Devices market is anticipated to have significantly impacted by the outbreak of the COVID-19 pandemic...
The ablation technology market is projected to reach USD 8.1 Billion by 2026 from USD 5.2 Billion in 2021, at a CAGR of 9.3% during the forecast period. The growing elderly population has also driven the incidence of target conditions and contributed to the demand for effective treatment. However, the reuse and reprocessing of devices in developed...
The artificial intelligence in healthcare market is projected to grow from USD 6.9 billion in 2021 to USD 67.4 billion by 2027; it is expected to grow at a CAGR of 46.2%from 2021 to 2027. Many companies are developing software solutions for various healthcare applications; this is the key factor complementing the growth of the software...
The global infection surveillance solutions market is to reach USD 1,033 million by 2026 from USD 508 million in 2021, at a CAGR of 15.2%. The growth in this market can primarily be attributed to the increasing incidence of HAIs and increasing surgical procedures. The rising healthcare expenditure, an increasing number of surgeries, the growing...
Medical Technology Density
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.